Choosing Blood Samples for Liquid Biopsy Research: A Biospecimen Sourcing Checklist
A liquid biopsy study begins well before a sample reaches the analyzer. Donor selection, collection materials, processing, and transport all help determine whether the specimen is suitable for the intended assay.
For researchers sourcing human blood samples, ordering “oncology plasma” or “healthy donor blood” is only a starting point. A useful sample request explains what the study will measure, which donor population it requires, and how the material must be handled.
The National Cancer Institute identifies differences in biospecimen collection, processing, storage, and associated data as factors that can affect research reproducibility. Addressing these details during sourcing helps teams establish consistent expectations before collections begin. NCI Biospecimen Best Practices
Start With the Research Question
Liquid biopsy research can involve circulating tumor DNA, other cell-free nucleic acids, circulating cells, extracellular vesicles, or soluble biomarkers. The sample specification should follow the target and analytical workflow.
Before requesting material, define:
- The analyte or biomarker being measured
- The assay platform and extraction method
- Whether the project involves discovery, assay development, or validation
- The required specimen format and input volume
- Whether collection and processing must follow an existing study protocol
An assay requiring isolated plasma presents a different sourcing request from one requiring whole blood delivered to the research laboratory. State who will perform each processing step so responsibilities are clear.
Choose Plasma or Serum Deliberately
Plasma and serum should not be treated as interchangeable starting materials.
For circulating tumor DNA mutation analysis, research comparing matched plasma and serum samples found that serum contained more background DNA and performed less well for detecting mutations at low allele frequencies. This supports choosing plasma for prospective ctDNA studies, while recognizing that archived serum may still have uses when its limitations are understood. Pittella-Silva et al., Clinical Chemistry
Other biomarkers require their own matrix assessment. A choice made for a ctDNA assay should not automatically become the default for a protein or RNA study.
Specify the matrix required by the intended method, and identify any proposed substitution before purchasing samples.
Define the Donor Cohort
A disease label alone may leave important questions unanswered. For oncology research, a request might need to distinguish active disease from remission, specify cancer stage, or establish the relationship between collection and treatment.
Depending on the study, donor criteria may include:
- Diagnosis and how it is documented
- Disease stage or status
- Current and prior treatment
- Timing of collection relative to treatment
- Age range and other demographic criteria
- Inclusion and exclusion requirements
Separate mandatory criteria from preferred characteristics. This gives the sourcing team a clearer basis for evaluating feasibility, timelines, and available inventory.
Healthy donor samples may support controls and early workflow development, but they do not establish performance in a disease-state population. Choose comparison groups around the intended research question.
Match the Collection Tube to the Workflow
Identify the exact collection tube and additive rather than requesting only “blood tubes.”
NCI’s cell-free DNA guidance distinguishes EDTA collections from cfDNA-stabilizing tubes and connects tube selection with anticipated processing delays. The appropriate choice depends on the collection-to-processing interval and the downstream method. NCI Cell-Free DNA: Biospecimen Collection and Processing
Include the tube manufacturer, product identifier, required fill volume, and handling instructions in the collection specification. For studies measuring several analyte classes, confirm compatibility with each intended assay.
Agree on Processing and Transport Requirements
Collection, plasma separation, storage, and delivery should form one documented workflow.
For cfDNA studies, NCI guidance addresses processing delays, centrifugation, plasma transfer, storage, and freeze-thaw exposure. These steps should be defined in an appropriate standard operating procedure. NCI cfDNA Guidance
Agree on the required processing interval, temperature conditions, separation method, and shipping format before collection. Plan aliquot sizes around the assay’s input requirements to limit unnecessary thawing.
For example, a request for a total plasma volume should also explain whether that volume is needed in one container or several aliquots. Include material needed for quality assessment, repeat testing, and any planned additional assays.
Request Documentation That Supports Interpretation
Sample records should allow researchers to connect analytical results with the specimen’s collection and handling history.
BLOODPAC recommends standardized preanalytical data elements for liquid biopsy datasets, emphasizing the importance of consistent information about how samples were obtained and processed. BLOODPAC Recommended Preanalytic Data Elements
Determine which records your project needs before placing the order. These may include coded donor and specimen identifiers, collection and processing timestamps, tube information, storage history, available quality-control results, and protocol deviations.
Also confirm which clinical details are available. Missing treatment or disease-status information can limit a sample’s usefulness even when its physical specifications meet the request.
A Liquid Biopsy Biospecimen Sourcing Checklist
Use these questions to prepare a sample request:
- What analyte and assay will the samples support?
- Is the required material whole blood, plasma, serum, or another fraction?
- Which donor and disease characteristics are mandatory?
- What collection tube and additive are required?
- Who will process the material, and under which protocol?
- What processing interval and temperature conditions are acceptable?
- What volume and aliquot format are needed per donor?
- Which quality measures and supporting records are required?
- Are repeat collections or matched specimens needed?
- What delivery schedule fits the laboratory workflow?
A complete specification helps the supplier identify suitable material and flag constraints early. It also gives the research team a consistent basis for accepting samples and interpreting results.
Discuss Your Blood Sample Requirements With CGT Global
CGT Global offers human whole blood sourcing options that include healthy and selected disease-state donors, specialty collection tubes, and project-specific collection requirements. Prospective projects can be evaluated for donor criteria, sample volume, processing needs, and delivery requirements. Explore Human Whole Blood Options
If your liquid biopsy study requires a specific donor population or collection workflow, share the assay requirements and sample specification with our team. Availability and project feasibility can then be reviewed before collection begins.
